TELA Bio, Inc. — Form 8-K
Filed August 31, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Roberto Cuca, COO/CFO, stepped down effective August 31, 2026. TELA Bio announced a cost reduction initiative targeting $17.0 million in annual operating expense reductions (18% of operating costs) through ~20% headcount reduction and external resource streamlining. One-time restructuring charge of ~$1.5 million expected in Q3 2026; company expects cost cuts to extend cash runway into 2028.
Why this rating
Leadership departure plus 18% expense cut is material at ~$77M market cap. Restructuring costs and headcount reduction signal cash pressure, though runway extension is positive. Significant execution risk on cost targets and integration of new CFO/COO role.
Tradability signal
SHORT
conviction 31/100 · expected -0.80% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (13 in this cell) moved +2.34% in the called direction over 4 hrs; shrunk for sample size that's a +0.80% edge. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
at our read · unknown $0.70 | +10 min · unknown $0.70 ▲ 0.00% | +30 min · unknown $0.70 ▲ 0.00% | +1 hr · unknown $0.70 ▲ 0.00% | +4 hrs · unknown $0.80 ▲ 14.29% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.